Exocrine Pancreatic Insufficiency (EPI) in Cats — Management Guide

Comprehensive, practical guide on feline EPI: causes (often chronic pancreatitis), diagnosis (fTLI), enzyme and B12 therapy, diet, monitoring and prognosis.

Quick Overview

What it is

Exocrine pancreatic insufficiency (EPI) in cats is a condition in which the pancreas does not produce enough digestive enzymes (lipase, proteases, amylase) to allow normal digestion. As a result, affected cats commonly develop weight loss, poor haircoat, diarrhea or loose stool and nutrient deficiencies despite a good or ravenous appetite.

Who's at risk

• EPI is much less common in cats than in dogs; when present in cats it is often secondary to chronic pancreatitis or pancreatic acinar atrophy.
• Middle-aged to older cats are more likely when chronic pancreatitis is the cause. No single breed is strongly over-represented, but individual case series note sporadic occurrences across breeds.

With timely diagnosis and appropriate lifelong management (pancreatic enzyme replacement and cobalamin supplementation), many cats regain weight, have improved stool quality and maintain a good quality of life. Response rates reported in clinical series are generally favorable (majority show clinical improvement), but long-term success depends on owner compliance, addressing concurrent disease (chronic pancreatitis, inflammatory bowel disease, hepatic disease), and monitoring.

This guide is for educational purposes. Always consult your veterinarian for diagnosis and treatment.

Pathophysiology — explained simply

The exocrine pancreas produces enzymes needed to break down fats, proteins and carbohydrates in the small intestine. In EPI, insufficient enzyme production means food passes through the gut incompletely digested. Undigested fat and protein in the intestine cause loose, greasy stool (steatorrhea), nutrient loss and weight loss. In cats, chronic inflammation of the pancreas (chronic pancreatitis) is a common cause: repeated or ongoing damage to pancreatic acinar cells gradually reduces enzyme output.

Loss of pancreatic function also predisposes to secondary problems: small intestinal bacterial overgrowth or dysbiosis, and deficiencies of fat-soluble vitamins and cobalamin (vitamin B12), which rely on normal pancreatic and intestinal function for absorption.

Breed-specific risk factors and prevalence

• Prevalence: EPI is rare in cats compared with dogs. Precise prevalence is not well established because older reports and many referral populations are small, but case series and referral data indicate significantly fewer feline cases.
• Breed risk: Unlike dogs (where German Shepherds are predisposed), no strong, consistent breed predisposition is established in cats. EPI is most commonly seen as a sequel to chronic pancreatitis, which can affect any breed.

Symptoms and clinical stage

Common clinical features

• Progressive weight loss despite normal or increased appetite (ravenous eating is common)
• Poor haircoat, flatulence, and unkempt appearance
• Loose, voluminous or greasy feces; often malodorous
• Increased stool frequency or intermittent diarrhea
• Occasionally vomiting

• Muscle wasting, weakness
• Signs related to concurrent diseases (e.g., lethargy, icterus if concurrent cholangitis)

There is no widely used numeric staging system for feline EPI. Clinicians classify severity by clinical signs (mild to severe weight loss and malnutrition), laboratory evidence (degree of cobalamin deficiency), and response to therapy. The presence of concurrent chronic pancreatitis or inflammatory bowel disease worsens prognosis and can complicate management.

Diagnostic approach

EPI should be suspected in any cat with unexplained weight loss and chronic loose or greasy stools, particularly when appetite is normal or increased.

• CBC, serum biochemistry, urinalysis — to assess concurrent disease (kidney or liver disease) and general health.
• Thyroid testing (hyperthyroidism) in older cats as an alternate cause of weight loss.

• Feline trypsin-like immunoreactivity (fTLI) is the test of choice. A low fTLI result (below the lab’s reference interval) is diagnostic of EPI. Many reference labs consider values substantially below the lower limit (commonly cited thresholds ~<8 µg/L in published literature) to be consistent with EPI; always interpret versus the lab's reference range.
• Fecal testing for fat (qualitative) is of limited sensitivity but may support clinical suspicion.

• Serum cobalamin should be measured because deficiency is common in EPI and requires supplementation. Low B12 is associated with poorer prognosis if untreated.

• Abdominal ultrasound is useful to look for pancreatic enlargement, chronic changes (fibrosis), concurrent cholangitis/hepatitis, or intestinal disease. Ultrasound may be normal despite EPI.
• If results are ambiguous or the patient fails to respond to treatment, referral to a veterinary internal medicine specialist for advanced imaging (repeat ultrasound, CT), endoscopic evaluation, or intestinal/pancreatic biopsy may be indicated.

Sources: ACVIM consensus (pancreatitis), JVIM and Merck Vet Manual.

Treatment options

Goals: Replace digestive enzymes, correct nutrient deficiencies (especially cobalamin), manage concurrent disease (chronic pancreatitis, inflammatory bowel disease), and support nutrition.

• Products: Pancrelipase (porcine-derived) products are used (examples: Viokase products, generic pancrelipase powders). Enteric-coated formulations for people exist but veterinary powders are commonly used.
• Administration: Powdered enzymes are mixed into the meal immediately before feeding or empty capsules opened and sprinkled on food. Avoid mixing too far in advance (enzyme activity degrades).
• Dosing concepts for cats: Start low and titrate. Typical starting approaches used in practice: 1/8 to 1/4 teaspoon of powdered pancrelipase per meal (or one small capsule worth) with food, given 2–3 times daily depending on meal frequency. Increase every 1–2 weeks until stool quality and weight improve. Some clinicians titrate to effect rather than a fixed mg/kg regimen.
• Monitoring: Improvement in stool quality and weight is expected within 2–4 weeks; continued improvement over several months is common. If no response, consider inadequate dosing, poor mixing with food, enzyme inactivation (e.g., by antacids or gastric acid), owner compliance, or concurrent disease.

• Rationale: B12 deficiency is common because pancreatic factors help protect intrinsic factor and B12 absorption. Supplementation often dramatically improves appetite, energy and intestinal health.
• Common protocol: Cyanocobalamin 250 µg (0.25 mg) subcutaneously once weekly for 4–6 weeks, then recheck serum cobalamin and often continue monthly injections if levels remain low or if clinical response was positive. Some clinicians use 250 µg every 2–4 weeks long-term; tailor to lab results and clinical response. Oral cobalamin may be considered but parenteral therapy is more reliable in malabsorptive states.

• If clinical or diagnostic evidence suggests bacterial overgrowth/dysbiosis or concurrent inflammatory bowel disease, short courses of antibiotics (e.g., tylosin 10–15 mg/kg PO q12–24h) may be tried under veterinary guidance. Probiotics can be adjunctive but evidence is variable.

• Diet selection: Focus on highly digestible, palatable diets. Historically fat restriction was recommended, but many cats with EPI tolerate moderate-fat diets if enzymes are given with each meal. The key is highly digestible protein and fat, consistent feeding schedule, and matching enzyme dosing to each meal.
• Meal frequency: Offer 2–4 small meals per day rather than one large meal. Enzymes must be present with each meal.
• Treats/people food: Avoid large fatty treats that may worsen stool quality; keep diet consistent. If concurrent pancreatitis is active, temporarily reduce dietary fat per your veterinarian’s guidance.

• Appetite stimulants, antiemetics or anti-diarrheals may be used symptomatically.
• In cats with active chronic pancreatitis, immunomodulatory or anti-inflammatory therapy may be considered on a case-by-case basis by a specialist.

• There is no surgical cure for diffuse EPI. Surgery is reserved for addressing focal pancreatic masses or complications (biopsy, drainage) identified on imaging.

Long-term management and monitoring

• Regular recheck schedule: initially every 2–4 weeks until clinical stabilization, then every 3–6 months. Monitor weight, body condition score, stool quality, appetite and activity.
• Bloodwork: Periodic CBC/chemistry and re-check serum cobalamin at 1–3 month intervals after starting supplementation, then every 6–12 months.
• Dose adjustments: Titrate enzyme dose to clinical effect — the lowest effective dose that maintains normal stool and weight.
• Address concurrent disease: If chronic pancreatitis or intestinal disease is present, work with your vet to optimize anti-inflammatory or immunomodulatory therapy as needed.

Prognosis and quality of life

• Most cats with EPI that are diagnosed and treated appropriately (enzymes + cobalamin) improve clinically — weight gain, normalized feces and improved coat quality. Clinical response may be seen within weeks, with continued improvement over months.
• Long-term outlook depends on the presence and severity of concurrent diseases (chronic pancreatitis, IBD, hepatic disease). Cats with uncontrolled concurrent disease may have a guarded prognosis.
• Owner compliance (giving enzymes with every meal, follow-up B12 injections) is crucial for a good outcome.

Living with EPI — practical daily tips

• Give pancreatic enzymes with every meal. Mix the powder or capsule contents into a small portion of food immediately before offering.
• Keep a dosing diary for the first 4–8 weeks: record enzyme dose, stool quality, appetite, and weight to help dose adjustments.
• Administer B12 injections as prescribed — many cats feel noticeably better after B12 therapy. If you are comfortable and trained, some owners give injections at home; clinics can also administer them.
• Keep meals small and frequent; consistent diet improves enzyme matching and stool stability.
• Avoid abrupt diet changes. If a diet change is needed, transition slowly over 7–10 days while maintaining enzyme therapy.
• Store enzyme powders per product instructions (usually cool, dry place) and check expiration dates — enzyme activity declines with time.
• If your cat refuses medicated food, try hiding a small amount of the medicated food inside a favorite wet food to encourage uptake; some products are better accepted than others.

When to see your vet urgently

Seek immediate veterinary attention if your cat develops any of the following:

• Sudden inappetence/anorexia for >24–48 hours or inability to hold down food, especially in a previously responsive cat
• Repeated vomiting, signs of dehydration (sunken eyes, tacky gums), collapse or severe lethargy
• New jaundice (yellow gums/eyes/skin)
• Bloody diarrhea, visible abdominal pain, or severe worsening of clinical signs despite therapy

Working with specialists

Refer or consult an ACVIM or ECVIM diplomate (internal medicine specialist) when:

• Diagnosis is uncertain despite testing,
• The cat does not respond to appropriate enzyme and B12 therapy within a reasonable trial (4–6 weeks),
• Advanced diagnostics (repeat ultrasound, CT, endoscopy, biopsy) are needed to evaluate concurrent disease.

Key takeaways

• EPI in cats is rarer than in dogs and is commonly secondary to chronic pancreatitis.
• fTLI is the diagnostic test of choice; measure serum cobalamin at diagnosis and treat deficiencies.
• Lifelong pancreatic enzyme replacement and cobalamin supplementation are the mainstays of therapy; dietary management and addressing concurrent disease are essential.
• With good owner compliance and management, many cats regain weight and have a good quality of life.

References and further reading

• ACVIM consensus statement on pancreatitis in dogs and cats. J Vet Intern Med (2013).
• Merck Veterinary Manual: Exocrine Pancreatic Insufficiency in Animals.
• Peer-reviewed case series and reviews on feline EPI and fTLI (Xenoulis, Suchodolski, Steiner and colleagues).

Frequently Asked Questions